Right Way To Drink Water: पानी पीने का सही तरीका

Drinking Water In Standing Is Bad?: आपकी प्यास बुझाने के लिए पानी जैसा कुछ नहीं है.

यह आपको हाइड्रेटेड रखने में मुख्य भूमिका निभाता है और जैसा कि आप जानते हैं, बहुत सारी स्वास्थ्य समस्याएं और अन्य संबंधित बीमारियां भी हैं, जिन्हें हल किया जा सकता है अगर आप नियमित रूप से पानी का सेवन करते रहें.

संपूर्ण स्वास्थ्य को हेल्दी रखने के लिए आपको हर दिन कम से कम 8 गिलास पानी पीना चाहिए.

शरीर को स्वस्थ और फिट रखने में पानी की अहम भूमिका होती है.

हर दिन कम से कम 8 गिलास पानी पीना चाहिए

मानव शरीर में पानी की मात्रा 50-60 प्रतिशत होती है. पानी शरीर के अंगों और ऊतकों की रक्षा करता है. साथ ही कोशिकाओं तक पोषक तत्व और ऑक्सीजन पहुंचाने का काम भी करता है.

Picture: Pixabay

हालांकि, सभी जानते हैं कि अच्छी सेहत के लिए सही मात्रा में पानी पीना कितना ज्यादा जरूरी है.

आप एक दिन में कितना पानी पीते हैं यह काफी मायने रखता है लेकिन इसके साथ ही अच्छी सेहत के लिए इस बात का ध्यान रखना भी जरूरी है कि आप किस पोजीशन में पानी पीते हैं.

अधिकतर लोग खड़े होकर पानी पीते हैं. जो आपके स्वास्थ्य बुरा असर डाल सकता है.

आपको खड़े होकर पानी पीना चाहिए या बैठकर? | Should You Drink Water While Standing Or Sitting?

खड़े होकर पानी पीने से गठिया और अन्य बीमारियां हो सकती हैं. यह सुनिश्चित करने के लिए जबकि हमारे पास बताने के लिए कोई वैज्ञानिक प्रमाण नहीं है कि दोनों तरीकों में से कौन सा सही है.

हालांकि, अभी भी नीचे बैठकर पानी पीने की सलाह दी जाती है. जब हम खड़े होते हैं या चलते हैं, तो रक्त प्रवाह हमारे हाथ और पैरों की ओर अधिक होता है, जो पानी को पाचन तंत्र तक ठीक से पहुंचने में बाधा साबित हो सकता है.

Drinking Water In Standing Is Bad?: पानी शरीर के अंगों और ऊतकों की रक्षा करता है. 

खड़े होकर पानी पीने के नुकसान | Disadvantages Of Standing And Drinking Water

1. आयुर्वेद के मुताबिक, जब हम खड़े होकर पानी पीते हैं तो, इससे हमारे पेट पर अधिक प्रेशर पड़ता है, क्योंकि खड़े होकर पानी पीने पर पानी सीधा इसोफेगस के जरिए प्रेशर के साथ पेट में तेजी से पहुंचता है.

इससे पेट और पेट के आसपास की जगह और डाइजेस्टिव सिस्टम को नुकसान पहुंचता है.

इसके अलावा कहा जाता है कि खड़े होकर पानी पीने से शरीर को इससे मिलने वाले किसी भी न्यूट्रिएंट्स का फायदा नहीं मिस है.

2. जब आप खड़े होकर पानी पीते हैं, तो पानी जो सीधे गुश के साथ प्रणाली से गुजरता है, वास्तव में उन अंगों तक नहीं पहुंचता है जहां तक जाना चाहिए.

इसलिए, जो अशुद्धियां बाहर जाने वाली होती हैं, वे गुर्दे और मूत्राशय में जमा हो जाती हैं.

3. खड़े होकर पानी पीना शरीर को प्रकृति के साथ तालमेल से बाहर कर देता है और तंत्रिका तंत्र को ट्रिगर करता है, जिससे यह महसूस होता है कि यह खतरे का सामना कर रहा है.

पोषक तत्व वास्तव में इस तरह बेकार हो जाते हैं और आपका शरीर तनाव या किसी तनाव का सामना करने के लिए बाध्य होता है.

4. खड़े होकर पानी पीने से पानी प्रेशर के साथ पेट में जाता है, जिससे सभी इंप्योरिटीज ब्लैडर में जमा हो जाती हैं, जो किडनी को गंभीर नुकसान पहुंचता है.

5. पानी पीने का तरीका हमारी सेहत को कई तरह से प्रभावित करता है, क्योंकि पानी के प्रेशर से शरीर के पूरे बायोलॉजिकल सिस्टम पर प्रभाव पड़ता है. इससे जोड़ों के दर्द की समस्या हो जाती है.

स्वास्थ्य सम्बन्धी अन्य आर्टिकल पढने के लिए यहाँ क्लिक करे

6. जब हम बैठकर पानी पीते हैं तो हमारी मांसपेशियां और नर्वस सिस्टम बहुत रिलेक्स रहते हैं. साथ ही खाना जल्दी डाइजेस्ट हो जाता है.

7. इसलिए हमेशा बैठकर ही पानी पीने की कोशिश करें. इस तरह से पानी का फ्लो धीमा रहेगा और शरीर को जरूरी न्यूट्रिएंट्स भी मिलेंगे.

8. खड़े होकर पानी पीने से फेफड़ों पर भी बुरा असर पड़ता है क्योंकि इससे हमारे फूड पाइप और विंड पाइप में ऑक्सीजन की सप्लाई रूक जाती है.

अगर कोई शख्स लगातार खड़े होकर पानी पीता है तो उस व्यक्ति को फेफड़ों के साथ-साथ दिल संबंधी बीमारी होने की संभावना भी अधिक होती है.

9. खड़े होकर पानी पीने से प्यास कभी नहीं बुझती है. यही कारण है कि पानी पीने के कुछ मिनट बाद ही आपको फिर से प्यास लगने लगती है. इसलिए बेहतर होगा कि बैठकर आराम से पानी पिएं.

क्या है पानी पीने का सही समय | What Is The Right Time To Drink Water

1. उठते ही दो गिलास पानी पिएं2. अपने भोजन से 20-30 मिनट पहले एक गिलास पानी पिएं3. अपने शॉवर से पहले एक गिलास पानी पिएं4. सोने से पहले एक गिलास पानी पिएं5. वर्कआउट से पहले और बाद में एक गिलास पानी पिएं6. बोतल से पीने से बचें7. जब आप बीमार हों तो अधिक पानी पिएं

अस्वीकरण: सलाह सहित यह सामग्री केवल सामान्य जानकारी प्रदान करती है. यह किसी भी तरह से योग्य चिकित्सा राय का विकल्प नहीं है. अधिक जानकारी के लिए हमेशा किसी विशेषज्ञ या अपने चिकित्सक से परामर्श करें. एनडीटीवी इस जानकारी के लिए ज़िम्मेदारी का दावा नहीं करता है.
https://thehealthmaster.com/2021/01/18/right-way-to-drink-water-%e0%a4%aa%e0%a4%be%e0%a4%a8%e0%a5%80-%e0%a4%aa%e0%a5%80%e0%a4%a8%e0%a5%87-%e0%a4%95%e0%a4%be-%e0%a4%b8%e0%a4%b9%e0%a5%80-%e0%a4%a4%e0%a4%b0%e0%a5%80%e0%a4%95%e0%a4%be/

The Dehuroad Cantonment Board was established in 1958 and is a autonomous body controlled by the Government of India, Ministry of Defence.

The Cantonment Board of Dehuroad is divided into seven villages, each of which has a civil and military population.

As per Census 2011 the population figure of Dehuroad Cantonment is 48961 which includes military population also

The Dehuroad Cantonment Board invites the offline applications in prescribed format from eligible candidates for direct recruitment to the below mentioned posts.

Complete applications in all respects should reach to the Office of the Cantonment Board, Dehuroad, Near Dehuroad Railway Station, Dehuroad, Pune - 412101 (Maharashtra).

Post: Pharmacy officer

No. of Posts : 1Category wise vacancy : UR-1

Pay Scale (as per 7th Pay Commission) : Rs. 29200-92300 (Level: S-10)Age Limits : 21-30 years

Required Educational Qualification1. Degree in Pharmacy from recognized University/ Institute.2. Registration with State Pharmacy Council or State Medical faculty.

Application Fee :-Application fee will be paid through Demand Draft in favour of Chief Executive Officer, Dehuroad Cantonment Board, payable at Dehuroad from Nationalized Bank Only.

The application fee once paid shall not be refunded under any circumstances and will not be used for any future recruitment process.General/UR : 700/-

Mode of Selection :-a. For all above posts except Resident Medical Officer:-

The selection and merit will be based on written test only (The written test will be of 100 marks of Objective Type Questions having duration of 90 minutes).

Answer to the questions will have to be marked on OMR Answer sheet.

b. Skill Test (Qualifying nature only) :- The candidates, who will qualify written test/ shortlisted will have to appear/undergo for the skill test mandatorily.

c. For Resident Medical Officer :- Selection will be subject to the performance of candidate in Interview/Personality Test.

d. Medium of Examination :- The questions for examination for all posts except Resident Medical Officer will be in English and Hindi (Bilingual).

The qualifying criteria/passing mark/qualifying marks in skill test will be set by appointing authority.

Candidates who will obtain the qualifying/passing marks in the skill test will be considered for final ranking of selection as per marks obtained/secured by them in Written Examination.

The skill test will beof qualifying nature and mark secured in skill test will not be considered for final ranking/selection.

The marks obtained in written test only will be considered for final ranking/selection. Candidates should note that there will be penalty (negative marking) for wrong answers marked by a candidate in the Objective Type Questions.

There are four alternatives for the answer to every question.

For each question for which a wrong answer has been marked by the candidate, one-third (0.33) of the marks assigned to that question will be deducted as penalty.

If a candidate marks more than one answer for single question, it will be treated as a wrong answer even if one of the marked answer happen to be correct and there will be same penally as above for that questions.

If a question is left blank i.e. no answer is marked by the candidate, there will be no penalty for that question.

Syllabus for written examination :-Reasoning and Quantitative AptitudeGeneral AwarenessEnglish ComprehensionSubject related to B. Pharmacy

General Conditions / Instructions / Informationa. The service of the appointed candidate / person will be governed under Cantonment Board Employees Service Rules 2021, Cantonment Act 2006 and Central Civil Service (Pension) Rules 2021 as amended from time to time by the Central Government as are applicable to employees of Cantonment Board.

b. If the candidate is applying for the more than one post than he/she has to sent Separate application each post.

c. Qualification acquired by the candidates should be strictly in accordance with the prescribed qualifications and the candidates should not seek claim equivalent of their qualification with that of the prescribed qualification.

d. No request for change of any entries or part, originally indicated in the application form shall be entertained.

e. The candidates should mention a valid email ID and a working Mobile Number in application form.

The candidates are advised not to change the email ID or Mobile Number during the process of recruitment.

They are also advised not to give email id / mobile number of any unknown person to avoid any complications.

f. I he candidates shall be held responsible for correctness of all information given by him / her and in case of any information / documents found to be incorrect at a later stage; action shall be taken against the candidates including dismissal from service.

g. No correspondence in regard to the appointment will be entertained.

h. No representation on any ground for non-appearance for the test etc. by the candidates will be entertained and his / her candidature will not be considered in such an eventually.

i. Persons already employed should sent applications through proper channel.

j. The candidate should not have been convicted by any court of law.

k. Incomplete applications without relevant documents, signatures and applications received after due date shall summarily rejected.

l. TA/DA will not be admissible for attending tests etc. as the case may be.

m.The candidates will have to make their own arrangement for stay etc.

n. Number of vacancies / posts may vary as per administrative exigencies / approvals.

o. The mobile phones / pagers / bluetooth devices/Smart watches etc. are strictly prohibited at the time of test.

p. The candidates are advised to visit the website from time to time on https://tlelniroad.cantt.gov.in for list of selected / rejected / shortlistedcandidate for Written Examination / Interview / Personality Test / Skill Test and further instructions / directions / amendments etc.

q.The candidates should note that their admission to examination will be purely provisional based on information given by candidates in application. This will be subject to all the eligibilities candidates by the recruiting authority.

r. The Chief Executive Officer/ Board reserves the right to recruiting processing in full or part without assigning any reason whatsoever.

s. The decision of appointing authority i.e. Chief Executive Officer/Board would be final with regard to all matters connected with the recruitment.

t. Candidates will not take any benefits of typographical errors in advertisement.

u. The appointing authority reserves the right to postpone / cancel / suspend/ terminate the recruitment process without any prior notice/assigning any reason at any stage. No correspondence would be entertained in this regard.

v. If there are two or more candidates in the same category having equal marks in the examination/interview/personality test etc., the candidate older in age will get preference.

w. The appointing authority shall draw a reserve panel/waiting list addition to the number of candidates selected as per the notified vacancies.

The reserve panel/waiting list shall be valid for a period of one year from the date of declaration of result and the vacancies arising due to non-acceptance of the offer to appointment.

Candidates not joining the post after acceptance of appointment of the candidates not being found eligible for appointment after verification of documents/certificates of due to registration of selected candidates within one year of joining the post, the same shall filled up from this reserve panel/waiting list

All the applicants / candidates are required to be present well in advance time on the date & venue before the commencement of written examination / interview /personality test / skill test. Any lapse in presence will be recorded as absent.

Application of the candidate/s who tries to bring any external/internal influence in the form of any means (monetary in kind or otherwise), shall be rejected. Selection shall be based on merit only.

Duly self-attested photocopies of the following documents / certificates to be attached sequentially with application form:-

a. Marksheets/ certificates of the essential educational qualification mentioned in above table in front of respective posts.

b. Matriculation/Secondary School Examination Certificate or an equivalent certificate for date of birth proof.

c. Two self-addressed envelopes of size 5” x 11” duly affixed Rs.10/- postal stamp

d. One Passport Size Photo pasted in given space on application form and two Passport Size Photos with name on backside stapled on front top of the application form

e. Caste Certificate, if applicable

f. If candidate applying for PH, copy of Disability / Medical Certificate issued by competent authority specifying percentage of disability

g. In the case of EWS - Income & Asset Certificate issued by competent authority as described in Department of Personnel and Training's Office Memorandum No.36039/1/2019-Estt (Res) dated 31st January, 2019

h. In the case of Ex-serviceman:- Discharge certificate from service, copy of Pension PPO and copy of Ex-serviceman identity card.

Candidates are requested to download the application form from the above mentioned website. The duly tilled application form along with self-attested copies of documents mentioned should be sent by Ordinary Post / Registered Post / Speed Post only on the below mentioned address:-

The Chief Executive OfficerOffice of the Dehuroad Cantonment Board,Near Dehuroad Railway Station,Dehuroad, Pune — 412101 (Maharashtra)The application should reach in prescribed time limit. The Dehuroad Cantonment Board is not responsible for postal delay.

(Any application received after time limit or through other channel viz. e-mail / by hand / courier will be rejected or not considered).

Candidates must clearly write on the top of the envelope “APPLICATION FOR THE POST OF................in category..................... (UR, SC, ST, OBC, EWS)” while submitting the application form.

Last Date for receipt of offline applications is 31/01/2023 till 06:00 pm

Application Form & More Info

Govt Job: For M.Pharm B.Pharm at NPPA

Govt Job: For M.Pharm, MS Pharm as JRF at DPSRU

Govt Job: For Technical Officer at WHO – World Health Organization

Govt Job: For M.Pharm or M.Sc at IPC – Salary upto Rs. 2,08,700 pm

Govt Job: For Pharmacists at District Health Society

Govt Job: For M.Pharm, MSc as Senior Project Associate at IIIM
https://thehealthmaster.com/2022/12/30/govt-job-for-pharmacy-officer-at-ministry-of-defence-pay-upto-rs-92300-pm/

Lupin Pharmaceuticals Inc. is voluntarily recalling four (4) lots of Quinapril Tablets to the patient (consumer/user) level due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level.

To date, Lupin has received no reports of illness that appear to relate to this issue.

Lupin discontinued the marketing of Quinapril tablets in September 2022.

Click for more articles on USFDA

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products, and vegetables.

Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.

Quinapril tablet USP is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure.

Click for more articles on Nitrosamines Impurity

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Quinapril Tablets USP 20mg, and 40mg is packaged in 90 count bottles and was distributed nationwide in the US to wholesalers, drug chains, mail order pharmacies and supermarkets. The recalled lots are included in the table below:

ProductLot NoExpiryNDCUPCDistribution DatesQuinapril Tablets USP, 20mgG10292904/202368180-558-09(90’s)36818055809503/15/2021         –09/01/2022Quinapril Tablets USP, 40mgG100533G100534G20307112/202212/202203/202468180-554-09(90’s)368180554097

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (USFDA).

Product Label: (see images below)

Other drugs recall

Drug recall: This Blood Pressure tablets recalled

Drug recall: Sodium Bicarbonate Injection recalled due to this reason

Drug recall: Dr Reddy’s, Sun Pharma recall these drugs due to this reason

Drug recall: FDA issues nationwide recall for Ferric Carboxymaltose

Drug recall: These drugs recalled by Aurobindo for this reason

Drug recall: These products recalled by Dr Reddy’s, Cipla, and Aurobindo

USFDA approves this monoclonal antibody to treat multiple sclerosis

CDSCO orders audits of Pharma Manufacturers & Importers for Pharmacovigilance system

IPC launches 10 new impurities standards

NPPA releases draft calculation sheet for ceiling price revision of 35 formulations

CDSCO and States starts joint inspections of Drug Manufacturing Units

DCGI calls for registering (MDTLs) Medical Devices Testing Laboratories

Confession in criminal proceedings: Ground for conviction ?

Registration for sale of Medical Devices: Procedure and conditions

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/30/drug-recall-4-lots-of-quinapril-tablets-recalled-due-to-this-reason/

The National Pharmaceutical Pricing Authority (NPPA) is a government regulatory agency that controls the prices of pharmaceutical drugs in India.

The National Pharmaceutical Pricing Authority (NPPA) was constituted by Government of India Resolution dated 29th 29, 1997 as an attached office of the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, as an independent regulator for the pricing of drugs and to ensure the availability and accessibility of medicines at affordable prices.

Posts: Consultant - Pharma & Medical Device

Sr. Consultant (Pharma) : 02 Post

Essential Qualification : A Master Degree in Pharmacy from any recognized University-national or foreign.

Experience: 4 years post-qualification work experience in Pharma Regulatory Affairs, Pharma Pricing, Pharma Production, Pharma Data Analysis, Drug Delivery, and Pharmaceutical Research and related subjects.

Good knowledge of working in MS Office and having good communication skills

Upper Age : Limit 40 years

Consultant (Medical Device) : 01 Post

Essential Qualification : A Bachelor Degree in Bio–Medical Engineering from any recognized University-national or foreign.

Experience : 2 years post qualification work experience in the field of Medical Devices Regulatory Affairs / Medical Devices Pricing / Medical Devices Production / Medical Devices Data Analysis and Research in the field of Medical Devices and related subject.Good knowledge of working in MS Office and having good communication skills

Upper Age Limit : 35 years

Young Professionals (Medical Device)

Post:- 02 Post

Essential Qualification A Bachelor Degree in Bio–Medical Engineering from any recognized University-national or foreign.

Experience : 2 years post qualification work experience in the field of Pharma Regulatory Affairs / Pharma Pricing / Pharma Production / Pharma Data Analysis / Drug Delivery and Research in the field of Pharmaceuticals and related subject. Good knowledge of working in MS Office and having good communication skills

Upper Age Limit  : 32 years

General Terms and Conditions1. Candidates shall be hired on contractual basis for a given period of work or for a period upto 01 year.

This term can be extended upto 03 years depending on the satisfactory performance of the candidate or need of the office/NPPA.

2. Eligibility of the Sr. Consultants / Consultants (Non-Tech, Grade-II) / Consultants/ Young Professionals is enclosed at Annexure-B and format of application is at Annexure-C.

3. (a) The monthly consultancy fees shall be as under:-Sr. Consultant – Rs. 60,000/- fixedConsultant – Rs. 50,000/- fixedConsultant (Non –Tech, Grade-II) – Rs. 65,000/- fixedYoung Professionals- Rs. 40,000/- fixed

(b) The consolidated fee will include applicable taxes and no other allowance will be paid. In case of retired Govt. Servant appointed as consultant, the consultancy fee shall be decided as per the relevant rules of Govt of India subject to the ceiling mentioned in 3(a) above.

(c) The Sr. Consultants / Consultants (Non-Tech, Grade-II) / Consultants/ Young Professionals shall not be eligible for any claim or any other benefit/compensation under provisions of any Act/Rules applicable to regular government employees.

The engagement does not grant the Consultant any right for future employment/regularization in NPPA/ Govt of India or any benefits admissible to the regular employees of NPPA.

The Sr. Consultants / Consultants (Non-Tech, Grade-II) / Consultants/ Young Professionals shall not be entitled to any benefit like Provident Fund, Pension, Gratuity, Medical Attendance Treatment, Seniority, Promotion etc, or any other benefits available to the NPPA employees on regular basis.

In addition, terms of engagement of retired government employees will be governed by Ministry of Finance O.M dated 09th December 2020.

(d) Annual Increment of 5% on initial consolidated fee may be awarded to the Sr. Consultants / Consultants( Non-Tech, Grade-II) / Consultants/ Young Professionals on completion of one year of service and who have been considered for continuation of service for subsequent year based on satisfactory performance on as recommended by their respective Reporting Officer.

The annual increment shall not be applicable to the retired government employee for the post of Consultants ( Non-Tech, Grade-II).

4. Tax Deduction at Source: The income tax or any other tax liable to be deducted as per prevailing rule, will be deducted at source before releasing the payment and NPPA will issue TDS Certificate as the case may be.

The NPPA takes no liability for taxes or other contribution payable by the Individual Sr. Consultants / Consultants( Non-Tech, Grade-II) / Consultants/ Young Professionals on payment made under the contract.

5. TA/DA : - The Individual Sr. Consultants / Consultants( Non-Tech, Grade-II) / Consultants/ Young Professionals may be required to undertake domestic tours subject to approval of the Competent Authority and they will be allowed TA/DA reimbursement at par as admissible to the Under Secretary to the Government of India.

6. Leave: Individual Sr. Consultants / Consultants( Non-Tech, Grade-II) / Consultants/ Young Professionals shall be eligible for 12 no. of days leave during the period of one year on prorata basis besides the Gazetted holidays.

However, un-availed leave shall not be carried forward, in case of extension beyond one year. ‘No work no pay’ will be applicable during the period of contract, if more than prescribed leave is taken.

7. Standards of Conduct: The Sr. Consultants / Consultants( Non-Tech, Grade-II) / Consultants/ Young Professionals shall observe the general acceptable office etiquettes during the period of duty.

He/she shall keep themselves abreast of the latest developments/ rules / regulations pertaining to their domain and advice the officers of NPPA accordingly. Failure to comply with the Rules/ Regulations issued by NPPA would attract grounds for termination of the services.

8. Prohibition of Sexual Exploitation and Abuse : - During the performance of their duties, the individual Sr. Consultants / Consultants( Non-Tech, Grade-II) / Consultants/ Young Professionals shall comply with the Sexual harassment of Women at Workplace (Prevention.

Prohibition and Redressal) Act, 2013. Any breach of the provisions thereof shall be a ground for termination of services. Any further action may also be recommended for appropriate legal action.

Other Terms & Conditionsa. Candidates shall be selected by a Selection Committee set up by the Competent Authority.

b. The contract can be terminated at any time by NPPA giving one month’s notice without assigning any reason.

The services can also be terminated if the competent authority is dissatisfied with their performance.

c. The Sr. Consultants / Consultants( Non-Tech, Grade-II) / Consultants/ Young Professionals during the contractual period cannot accept/engage himself/herself in any other part-time job/ profession of whatsoever kind.

d. The Candidates shall perform the duties assigned to him/her. The competent authority reserves the right to assign any duty as and when required. No extra/additional allowance will be admissible in case of such assignment.

e. Basic support like office space, furniture, stationery, computer, access to internet etc. will be provided by NPPA so that assigned duties may be handled smoothly.

f. Selected personnel hired as Sr. Consultant /Consultants/ Consultant (Non-Tech, Grade II) and YPs will be sent selection letters through mail.

They would be required to join within prescribed period as indicated in the selection letter.

g. The Candidates shall not be entitled to any benefit like Provident Fund, Pension, Insurance, Gratuity, Medical Attendance Treatment, Seniority, Promotion etc. or any other benefits available to a Government Servant appointed on regular basis.

h. The Candidates will not be granted any claim or right or preference for regular appointment to any post in the Government set up.

i. The Candidates shall not be entitled to any TA for joining the appointment.

j. If any declaration given or information furnished by Candidates proves to be false or if he/she is found to have wilfully suppressed any material information, he/she will be liable for removal from such contract and also such other action as the Government may deem necessary.

k. The hiring/contract will be subject to physical fitness and the Candidates are required to submit a Medical Certificate from an MBBS doctor to this effect at the time of joining.

l. The applications should be sent to NPPA through Speed post/Registered post, Courier or in person only.

This Office will communicate with the candidates through e-mail only. Candidates are advised to keep checking their emails account regularly.

Incomplete applications or applications without self attested copies of certificates of qualifications, age, etc, are liable to rejected summarily.

Last Date of Closing : 21 days from the date of advertisement in the newspaper

Find More Info & Application Form

Govt Job: For M.Pharm, MS Pharm as JRF at DPSRU

Govt Job: For Technical Officer at WHO – World Health Organization

Govt Job: For M.Pharm or M.Sc at IPC – Salary upto Rs. 2,08,700 pm

Govt Job: For Pharmacists at District Health Society

Govt Job: For M.Pharm, MSc as Senior Project Associate at IIIM

Govt Job; For Pharmacists at District Health Society
https://thehealthmaster.com/2022/12/29/govt-job-for-m-pharm-b-pharm-at-nppa/

TG Therapeutics said that the US health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up 47 percent in afternoon trade.

The approval by the US Food and Drug Administration (USFDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company’s finances from the withdrawal of its lymphatic cancer drug earlier this year.

Click for more articles on USFDA

TG Therapeutics said it was expecting to launch the drug, branded as Briumvi, in the first quarter of 2023, but did not give details on its pricing.

Chris Howerton, an analyst, Jefferies, said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year.

In comparison, Roche’s Ocrevus has a current list price of about $68,000 annually.

Unlike other MS drugs that target T cells, Briumvi belongs to a class of drugs that tackles B cells’ role in driving the inflammation that is central to the neurological disease.

The approval, which comes with a warning of infusion reactions from the drug, was based on a late-stage study that showed the drug was effective in reducing annualized relapse rates in patients.

USFDA gives final approval to this breast cancer injection

USFDA gives approval for Fulvestrant injection

USFDA gives approval for this Genetic Disorder drug

USFDA gives approval for Lymphoma Therapy

USFDA gives approval for Pregabalin capsules

USFDA gives approval for Brivaracetam Tablets

CDSCO orders audits of Pharma Manufacturers & Importers for Pharmacovigilance system

IPC launches 10 new impurities standards

USFDA gives final approval to this breast cancer injection

NPPA releases draft calculation sheet for ceiling price revision of 35 formulations

CDSCO and States starts joint inspections of Drug Manufacturing Units

DCGI calls for registering (MDTLs) Medical Devices Testing Laboratories

Confession in criminal proceedings: Ground for conviction ?

Registration for sale of Medical Devices: Procedure and conditions

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/29/usfda-approves-this-monoclonal-antibody-to-treat-multiple-sclerosis/

The Indian Pharmacopoeia Commission (IPC) has launched 10 new impurity standards for effective quality control analysis of pharmaceutical products in the country.

With this, IPC will have a total of 410 impurity standards in its database, which is available for sale at www.ipc.gov.in for drug manufacturing companies and testing labs in the country.

“We are planning to increase the number of impurity standards in our IPC product catalog and have set the target of having 500 impurity standards by March 2023."

"Previously, manufacturers and other stakeholders sourced these standards from the British Pharmacopoeia or the US Pharmacopoeia (USP), but now IPC is making them available at standardized rates under one platform," says Dr. Rajiv Singh Raghuvanshi, secretary-cum-scientific director of IPC. 

Click for more articles on IPC

10 Impurity standards

The names of the impurity standards are:

- Dolutegravir-4-fluoro impurity,

- Ethyl paraben,

- Fumaric acid (Lamivudine and Tenofovir tablets),

- Ketorolac-1-hydoxy analog,

- Mesalazine impurity F,

- Fumaric acid (Maleic Acid),

- Methotrexate impurity A,

- Risperidone trans -N-oxide,

- Terbinafine related compound B

- Fumaric acid (Quetiapine Fumarate).

Click here to purchase impurity standards online

IPC in the month of July had launched the ninth edition of the Indian Pharmacopoeia (IP).

IP is recognized as the official book of standards for the drugs being manufactured and/or marketed in India.

IP contains a collection of authoritative procedures of analysis and specifications of drugs for their identity, purity and strength.

The standards of the IP are authoritative in nature and are enforced by the regulatory authorities for ensuring the quality of drugs in India.

During quality assurance and at the time of a dispute in court, the IP standards are legally acceptable.

The standards prescribed in the IP are to establish the article's compliance with regulatory requirements.

The determination of unwanted compounds in pharmaceuticals is critical to addressing the safety, quality, and purity of drug substances and finished products.

Types of impurities

International Council for Harmonization (ICH) Q3A – Q3E guidance outlines five primary categories for impurities associated with pharmaceuticals, which consist of:

- Impurities in new drug substances,

- Impurities in new drug products,

- Residual solvents,

- Elemental impurities,

- Extractables and leachables (E&L).

Effect of impurities

Impurities can affect the safety and efficacy of pharmaceuticals and biologic drugs, resulting in the potential recall of marketed drugs or the extension of drug development timelines, as these unwanted chemicals remain with the drug formulation or active pharmaceutical ingredient (API).

Impurities can be introduced from a variety of sources, from API and/or excipient degradation, to manufacturing processes, including process impurities, process aids, and residual solvents, or from container-closure contact and storage.

Drug impurities are unwanted chemicals that remain with the active pharmaceutical ingredients, develop during formulation, or occur during the aging process of both the active pharmaceutical ingredients and the formulation, and are subject to analysis and rigorous testing for quality assurance.

Latest Circulars: (IPC) Indian Pharmacopoeia Commission

Latest Notifications regarding Pharmaceuticals

Latest on National Formulary of India (NFI)

Safety alerts issued by IPC

IPC launches 10 new impurities standards

IPC releases amendment list for IP 2022, details here

IPC adds one IP Reference Standard & 20 new impurities to IP 2022

IPC adds 10 new Impurity Reference Substances to IP 2022

IPC launches 1000th IP Reference Standard

IPC adds 7 new Veterinary Monographs, 8 new Chemical Monographs to IP 2022

IPC adds 5 new IP Reference Standards & 7 new Impurities to IP 2022

IPC releases IP 2022, 92 new monograph, 27 APIs added: Read details

USFDA gives final approval to this breast cancer injection

NPPA releases draft calculation sheet for ceiling price revision of 35 formulations

CDSCO and States starts joint inspections of Drug Manufacturing Units

DCGI calls for registering (MDTLs) Medical Devices Testing Laboratories

USFDA gives approval for Fulvestrant injection

USFDA gives approval for this Genetic Disorder drug

Confession in criminal proceedings: Ground for conviction ?

Registration for sale of Medical Devices: Procedure and conditions

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/29/ipc-launches-10-new-impurities-standards/

Download Latest on National Pharmaceutical Pricing Authority (NPPA)

National Pharmaceutical Pricing Authority (NPPA) was constituted by a Government of India resolution dated August 29, 1997 as an attached office of the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, as an independent regulator for the pricing of drugs and to ensure the availability and accessibility of medicines at affordable prices.

It has been entrusted inter-alia, with the following functions:

- To implement and enforce the provisions of the Drugs Price Control Order (DPCO), 1995/2013  in accordance with the powers delegated to it.

- To undertake and/or sponsor relevant studies in respect of pricing of drugs/formulations.

- To monitor the availability of drugs, identify shortages, if any, and to take remedial steps.

- To collect/maintain data on production, exports and imports, market share of individual companies, profitability of companies etc. for bulk drugs and formulations.

- To deal with all legal matters arising out of the decisions of the Authority.

- To render advice to the Central Government on changes/revisions in the drug policy.

- To render assistance to the Central Government in the parliamentary matters relating to the drug pricing.

Click for more articles on NPPA

Drugs Prices Control Order, 2013 (DPCO 2013)

The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, notified the Drug (Prices Control) Order 2013 (DPCO 2013) in May 2013, which may fluctuate the pricing of 348 essential drugs. Prior to the 2013 regime, the DPCO 1995 included 74 bulk drugs within its ambit and the pricing of the drugs were fixed on the basis of manufacturing costs declared by the drug manufacturers.

The DPCO 2013 empowers the National Pharmaceutical Pricing Authority (NPPA) to regulate prices of 348 essential drugs. As per the DPCO 2013, all strengths and dosages specified in the National List of Essential Medicines (NLEM) will be under price control.

Para 2(i) of the DPCO 2013 defines the term "Formulation" as a medicine processed out of or containing one or more drugs with or without use of any pharmaceutical aids, for internal or external use for or in the diagnosis, treatment, mitigation or prevention of disease and, but shall not include –

- i. any medicine included in any bonafide Ayurvedic (including Sidha) or Unani (Tibb) systems of medicines;

- ii. any medicine included in the Homeopathic system of medicine; and

- iii. any substance to which the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) do not apply;

As per the DPCO 2013, "Scheduled formulation" means any formulation, included in the First Schedule whether referred to by generic versions or brand name. "Non scheduled formulation" has been defined as a formulation, the dosage and strengths of which are not specified in the First Schedule.

"Schedule" is the Schedule appended to the DPCO 2013.

Click to read more articles on DPCO 2013

Pricing of Scheduled Formulations:

Para 4 of the DPCO 2013 provides formula for the calculation of ceiling price of a scheduled formulation as follows –

Step1. First the Average Price to Retailer of the scheduled formulation i.e. P(s) shall be calculated as below:

Average price to retailer P(S) = (Sum of prices to retailer of all the brands and generic versions of the medicine having market share more than or equal to one percent of the total market turnover on the basis of moving annual turnover of that medicine) / (Total number of such brands and generic versions of the medicine having market share more than or equal to one percent of total market turnover on the basis of moving annual turnover for that medicine.)

Step2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as below:

P(c) = P(s). (1+M/100), where P(s) = Average Price to Retailer for the same strength and dosage of the medicine as calculated in step1 above. M = % Margin to retailer and its value =16

Calculation of Ceiling Prices of following has also been provided in the DPCO 2013.

- a. Ceiling price of a scheduled formulation in case of no reduction in price due to absence of competition

- b. Calculation of Retail price of a new drug for existing manufacturers of scheduled formulations.

Click to read more on NLEM

Pricing of Non-Scheduled Formulations:

Apart from the price fixation of the Scheduled Formulations, the NPPA is also empowered to monitor the maximum retail prices (MRP) of all the drugs, including the non-scheduled formulations and ensure that no manufacturer increases the maximum retail price of a drug more than ten percent of maximum retail price during preceding twelve months and where the increase is beyond ten percent of maximum retail price, it is empowered to reduce the same to the level of ten percent of maximum retail price for next 12 months. The manufacturer shall be liable to deposit the overcharged amount along with interest thereon from the date of increase in price in addition to the penalty.

Display of prices of Scheduled & Non-Scheduled formulations and price list:

Para 24 and 25 of the DPCO 2013 mandate that every manufacturer of a Scheduled & non-Scheduled formulation intended for sale shall display in indelible print mark, on the label of container of the formulation and the minimum pack thereof offered for retail sale, the maximum retail price of that formulation with the words "Maximum Retail Price" preceding it and the words 'inclusive of all taxes' succeeding it. Para 26 lays down that no person shall sell any formulation to any consumer at a price exceeding the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is less.

Recovery of overcharged amount under DPCO 1987 & 1995:

Para 23 states that notwithstanding anything contained in the order, the Government shall by notice, require the manufacturers, importer or distributor or as the case may be, to deposit the amount accrued due to charging of prices higher than those fixed or notified by the Government under the provisions of Drugs (Prices Control) Order, 1987 and Drugs (Prices Control) Order, 1995 under the provisions of this Order.

Margin of retailer & maximum retail price:

Para 7 lays down that while fixing a ceiling price of scheduled formulations and retail prices of new drugs, sixteen percent of price to retailer as a margin to retailer shall be allowed. Para 8 specifies that the maximum retail price of scheduled formulations shall be fixed by the manufacturers on the basis of ceiling price notified by the Government plus local taxes wherever applicable. Even the loose quantities of any formulation shall not be sold at a price which is in excess of pro-rata price of the formulation.

Click for latest notification of NPPA / DPCO

Click for more articles on DPCO

DPCO order

Drugs (Price Control) Amendment Order 2019

Drugs-Price-Control-Amendment-Order-2019

Drugs (Prices Control) Order, 2013 (DPCO)

Drugs-Price-Control-Order-2013

Drugs (Prices Control) Order, 1995 (DPCO)

Drugs-Price-Control-Order-1995

Drugs (Price Control) Order 1979 (DPCO)

Drugs-Price-Control-Order-1979

DPCO – Schedule-I

Click below link

Schedule-1 amendment S.O.-508E-dt-01-02-2021-Amendment-in-Schedule-I-of-the-DPCO-2013

Schedule-I – S.O.-701E-dt-10-03-2016-Drugs-Price-Control-Amendment-Order-2016-Regarding-Schedule-I-Drugs-and-doage-form

Price List

2022

S.O. 5939(E) dt 19-12-2022 NPPA has fixed the Ceiling price of 12 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022) based on the decision of 105th Authority meeting dated 15.12.2022

S.O.-5939E-dt-19-12-2022-NPPA-has-fixed-Ceiling-price-of-12-scheduled-formulations-under-Drugs-Prices-Control-Order-2013-NLEM-2022-based-on-the-decision-of-105th-Authority-meeting-dated-15.12.2022

S.O. 5938(E) dt 19-12-2022 NPPA has revised the Ceiling price of 107 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022) based on the decision of 105th Authority meeting dated 15.12.2022

S.O.-5938E-dt-19-12-2022-NPPA-has-revised-Ceiling-price-of-107-scheduled-formulations-under-Drugs-Prices-Control-Order-2013-NLEM-2022-based-on-the-decision-of-105th-Authority-meeting-dated-15.12.2022

S.O. 5937(E) dt 19-12-2022 NPPA has fixed retail prices of 10 formulations under Drugs (Prices Control) Order, 2013 based on the decision of the 105th Authority meeting dated 15.12.2022

S.O.-5937E-dt-19-12-2022-NPPA-has-fixed-retail-prices-of-10-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-105th-Authority-meeting-dated-15.12.2022

S.O. 5511 (E) dt 28-11-2022 NPPA has fixed retail prices of 01 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 104th Authority meeting dated 23.11.2022

S.O.-5511-E-dt-28-11-2022-NPPA-has-fixed-retail-prices-of-01-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-104th-Authority-meeting-dated-23.11.2022

S.O. 5388(E) dt 18-11-2022 NPPA has fixed retail prices of 40 formulations under DPCO 2013 based on the decision of the 103rd Authority meeting dated 10.11.2022.

S.O.-5388E-dt-18-11-2022-NPPA-has-fixed-retail-prices-of-40-formulations-under-DPCO-2013-based-on-the-decision-of-103rd-Authority-meeting-dated-10.11.2022.

S.O. 4595(E) dt 29-09-2022 Extension Revised ceiling price of Dextrose Injection in 100ml pack having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4595E-dt-29-09-2022-Extension-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4594(E) dt 29-09-2022 Extension Revised ceiling price of Mannitol Injection 20% in 100ml pack having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4594E-dt-29-09-2022-Extension-Revised-ceiling-price-of-Mannitol-Injection-20-in-100ml-pack-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4593(E) dt 29-09-2022 Extension Revised ceiling price of Metronidazole Injection IP in 100ml pack having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4593E-dt-29-09-2022-Extension-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4592(E) dt 29-09-2022 Extension of revised ceiling price of Ringer Lactate Injection having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4592E-dt-29-09-2022-Extension-of-revised-ceiling-price-of-Ringer-Lactate-Injection-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4591(E) dt 29-09-2022 Extension of revised ceiling price of IV Fluid Injection having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4591E-dt-29-09-2022-Extension-of-revised-ceiling-price-of-IV-Fluid-Injection-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4590(E) dt 29-09-2022 Extension of revised price of Liquid Medical Oxygen (LMO) and Oxygen Inhalation (Medicinal Gas) in cylinder under Drugs (Prices Control) Order, 2013 based on the decision of Authority meeting dated 27

S.O.-4590E-dt-29-09-2022-Extension-of-revised-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-Authority-meeting-dated-27

S.O. 4589(E) dt 29-09-2022 Extension of revised ceiling price of Heparin Injection under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4589E-dt-29-09-2022-Extension-of-revised-ceiling-price-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4588(E) dt 29-09-2022 NPPA has fixed retail prices of 40 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022

S.O.-4588E-dt-29-09-2022-NPPA-has-fixed-retail-prices-of-40-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4343(E) dt 15-09-2022 Notification regarding extension of Knee implants under Drugs (Prices Control) Order, 2013.

S.O.-4343E-dt-15-09-2022-Notification-regarding-extension-of-Knee-implants-under-Drugs-Prices-Control-Order-2013.

S.O. 4342(E) dt 15-09-2022 NPPA has fixed retail prices of 1 formulation under Drugs (Prices Control) Order, 2013 (WPA) based on the decision of 101st Authority meeting dated 07.09.2022.

S.O.-4342E-dt-15-09-2022-NPPA-has-fixed-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013-WPA-based-on-the-decision-of-101st-Authority-meeting-dated-07.09.2022.

S.O. 4341(E) dt 15-09-2022 NPPA has fixed retail prices of 36 formulations under the Drugs (Prices Control) Order, 2013 based on the decision of the 101st Authority meeting dated 07.09.2022.

S.O.-4341E-dt-15-09-2022-NPPA-has-fixed-retail-prices-of-36-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-101st-Authority-meeting-dated-07.09.2022.

OM dated 25.08.2022 relating to fixation of Ceiling Price of Sodium Chloride 0.45% Injection.

OM-dated-25.08.2022-relating-to-fixation-of-Ceiling-Price-of-Sodium-Chloride-0.45-Injection.

S.O. 4002(E) dt 24-08-2022 NPPA has fixed retail prices of 45 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 100th Authority meeting dated 05.08.2022.

S.O.-4002E-dt-24-08-2022-NPPA-has-fixed-retail-prices-of-45-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-100th-Authority-meeting-dated-05.08.2022.

S.O. dt 29-07-2022 Notification regarding extension of capping of trade margin of 5 Medical Devices

S.O.-dt-29-07-2022-Notification-regarding-extension-of-capping-of-trade-margin-of-5-Medical-Devices

S.O. 2983(E) dt 30-06-2022 Notification regarding extension of price regulation on Oxygen Concentrator

S.O.-2983E-dt-30-06-2022-Notification-regarding-extension-of-price-regulation-on-Oxygen-Concentrator

S.O. 2982(E) dt 30-06-2022 Notification regarding extension of price regulation on LMO and Oxygen Inhalation

S.O.-2982E-dt-30-06-2022-Notification-regarding-extension-of-price-regulation-on-LMO-and-Oxygen-Inhalation

S.O. 2981(E) dt 30-06-2022 NPPA has fixed the retail prices of 84 new drugs based on the decision taken in 99th Authority meeting dated 28.06.2022

S.O.-2981E-dt-30-06-2022-NPPA-has-fixed-the-retail-prices-of-84-new-drugs-based-on-the-decision-taken-in-99th-Authority-meeting-dated-28.06.2022

S.O. 2465(E) dt 30-05-2022 Notification regarding extension of TMR notification on Oxygen Concentrators

S.O.-2465E-dt-30-05-2022-Notification-regarding-extension-of-TMR-notification-on-Oxygen-Concentrators

S.O. 2166 (E) DT 09-05-2022 NPPA has revised retail price of 1 formulation under Drugs (Prices Control) Order, 2013 based on review order.

S.O.-2166-E-DT-09-05-2022-NPPA-has-revised-retail-price-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-review-order.

S.O. 2165(E) Dt 09-05-2022 NPPA has fixed retail prices of 18 formulations under Drugs (Prices Control) Order, 2013 the price of which were applied earlier in the 96th Authority meeting dated 24.03.2022.

S.O.-2165E-Dt-09-05-2022-NPPA-has-fixed-retail-prices-of-18-formulations-under-Drugs-Prices-Control-Order-2013-the-price-of-which-were-applied-earlier-in-the-96th-Authority-meeting-dated-24.03.2022.

S.O. 2164(E) Dt 09-04-2022 NPPA has fixed retail prices of 66 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 97th Authority meeting dated 06.05.2022.

S.O.-2164E-Dt-09-04-2022-NPPA-has-fixed-retail-prices-of-66-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-97th-Authority-meeting-dated-06.05.2022.

S.O. 1833(E) dt 18-04-2022 NPPA has fixed retail prices of 15 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022

S.O.-1833E-dt-18-04-2022-NPPA-has-fixed-retail-prices-of-15-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022

S.O. 1782(E) dt 12-04-2022 NPPA has fixed retail prices of 23 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022

S.O.-1782E-dt-12-04-2022-NPPA-has-fixed-retail-prices-of-23-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022

S.O. 1508(E) dt 30-03-2022 NPPA has fixed ceiling prices of Liquid Medical Oxygen, Medical Inhalation under Drugs (Prices Control) Order, 2013

S.O.-1508E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Liquid-Medical-Oxygen-Medical-Inhalation-under-Drugs-Prices-Control-Order-2013

S.O. 1507(E) dt 30-03-2022 NPPA has fixed ceiling prices of Heparin Injection under Drugs (Prices Control) Order, 2013

S.O.-1507E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013

S.O. 1506(E) dt 30-03-2022 NPPA has fixed ceiling prices of Dextrose under Drugs (Prices Control) Order, 2013

S.O.-1506E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Dextrose-under-Drugs-Prices-Control-Order-2013

S.O. 1505(E) dt 30-03-2022 NPPA has fixed ceiling prices of Mannitol under Drugs (Prices Control) Order, 2013

S.O.-1505E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Mannitol-under-Drugs-Prices-Control-Order-2013

S.O. 1504(E) dt 30-03-2022 NPPA has fixed ceiling prices of Metronidazole under Drugs (Prices Control) Order, 2013

S.O.-1504E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Metronidazole-under-Drugs-Prices-Control-Order-2013

S.O. 1503(E) dt 30-03-2022 NPPA has fixed ceiling prices of 9 formulations under Drugs (Prices Control) Order, 2013

S.O.-1503E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-9-formulations-under-Drugs-Prices-Control-Order-2013

S.O. 1502(E) dt 30-03-2022 NPPA has fixed ceiling prices of 2 Coronary stents under Drugs (Prices Control) Order, 2013

S.O.-1502E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-2-Coronary-stents-under-Drugs-Prices-Control-Order-2013

S.O. 1501(E) dt 30-03-2022 NPPA has fixed ceiling prices of 4 formulations under Drugs (Prices Control) Order, 2013

S.O.-1501E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-4-formulations-under-Drugs-Prices-Control-Order-2013

S.O. 1500(E) dt 30-03-2022 NPPA has fixed ceiling prices of 8 formulations under Drugs (Prices Control) Order, 2013

S.O.-1500E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-8-formulations-under-Drugs-Prices-Control-Order-2013

S.O. 1499(E) dt 30-03-2022 NPPA has fixed ceiling prices of 872 formulations under Drugs (Prices Control) Order, 2013

S.O.-1499E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-872-formulations-under-Drugs-Prices-Control-Order-2013

OM. dt 25-03-2022 Movement in Wholesale Price Index (WPI) for the preceding calendar year 2021

OM.-dt-25-03-2022-Movement-in-Wholesale-Price-Index-WPI-for-the-preceding-calendar-year-2021

S.O. 796(E) dt 18-02-2022 NPPA has fixed ceiling prices of 19 formulations under Drugs (Prices Control) Order, 2013

S.O.-796E-dt-18-02-2022-NPPA-has-fixed-ceiling-prices-of-19-formulations-under-Drugs-Prices-Control-Order-2013

S.O. 401(E)
https://thehealthmaster.com/2021/11/07/latest-on-national-pharmaceutical-pricing-authority-nppa/

Download - National Pharmaceutical Pricing Authority (NPPA)

The National Pharmaceutical Pricing Authority (NPPA) was constituted by Government of India Resolution dated August 29, 1997 as an attached office of the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, as an independent regulator for the pricing of drugs and to ensure the availability and accessibility of medicines at affordable prices.

It has been entrusted inter-alia, with the following functions:

- To implement and enforce the provisions of the Drugs Price Control Order (DPCO), 1995/2013  in accordance with the powers delegated to it.

- To undertake and/or sponsor relevant studies in respect of pricing of drugs/formulations.

- To monitor the availability of drugs, identify shortages, if any, and to take remedial steps.

- To collect/maintain data on production, exports and imports, market share of individual companies, profitability of companies etc. for bulk drugs and formulations.

- To deal with all legal matters arising out of the decisions of the Authority.

- To render advice to the Central Government on changes/revisions in the drug policy.

- To render assistance to the Central Government in the parliamentary matters relating to the drug pricing.

Click for more articles on NPPA

Drugs Prices Control Order, 2013 (DPCO 2013)

The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, notified the Drug (Prices Control) Order 2013 (DPCO 2013) in May 2013, which may fluctuate the pricing of 348 essential drugs. Prior to the 2013 regime, the DPCO 1995 included 74 bulk drugs within its ambit and the pricing of the drugs were fixed on the basis of manufacturing costs declared by the drug manufacturers.

The DPCO 2013 empowers the National Pharmaceutical Pricing Authority (NPPA) to regulate the prices of 348 essential drugs. As per the DPCO 2013, all strengths and dosages specified in the National List of Essential Medicines (NLEM) will be under price control.

Para 2(i) of the DPCO 2013 defines the term "Formulation" as a medicine processed out of or containing one or more drugs with or without the use of any pharmaceutical aids, for internal or external use for or in the diagnosis, treatment, mitigation or prevention of disease and, but shall not include –

- i. any medicine included in any bonafide Ayurvedic (including Sidha) or Unani (Tibb) systems of medicines;

- ii. any medicine included in the Homeopathic system of medicine; and

- iii. any substance to which the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) do not apply;

As per the DPCO 2013, "Scheduled formulation" means any formulation, included in the First Schedule whether referred to by generic versions or brand names. "Non-scheduled formulation" has been defined as a formulation, the dosage, and strengths of which are not specified in the First Schedule.

"Schedule" is the Schedule appended to the DPCO 2013.

Click to read more articles on DPCO 2013

Pricing of Scheduled Formulations:

Para 4 of the DPCO 2013 provides a formula for the calculation of the ceiling price of a scheduled formulation as follows –

Step1. First, the Average Price to the Retailer of the scheduled formulation i.e. P(s) shall be calculated as below:

The average price to retailer P(S) = (Sum of prices to the retailer of all the brands and generic versions of the medicine having market share more than or equal to one percent of the total market turnover on the basis of moving annual turnover of that medicine) / (Total number of such brands and generic versions of the medicine having market share more than or equal to one percent of total market turnover on the basis of moving annual turnover for that medicine.)

Step2. Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as below:

P(c) = P(s). (1+M/100), where P(s) = Average Price to Retailer for the same strength and dosage of the medicine as calculated in step 1 above. M = % Margin to retailer and its value =16

Calculation of Ceiling Prices of the following has also been provided in the DPCO 2013.

- a. Ceiling price of a scheduled formulation in case of no reduction in price due to the absence of competition

- b. Calculation of Retail price of a new drug for existing manufacturers of scheduled formulations.

Click to read more on NLEM

Pricing of Non-Scheduled Formulations:

Apart from the price fixation of the scheduled formulations, the NPPA is also empowered to monitor the maximum retail prices (MRP) of all the drugs, including the non-scheduled formulations, and ensure that no manufacturer increases the maximum retail price of a drug more than ten percent of the maximum retail price during the preceding twelve months, and where the increase is beyond ten percent of the maximum retail price, it is empowered to reduce the same to the level of ten percent of the maximum retail price for the next 12 months.

The manufacturer shall be liable to deposit the overcharged amount along with interest thereon from the date of the increase in price in addition to the penalty.

Display of prices of Scheduled & Non-Scheduled formulations and price list:

Paragraphs 24 and 25 of the DPCO 2013 mandate that every manufacturer of a scheduled or non-scheduled formulation intended for sale shall display, in indelible print, on the label of the container of the formulation and the minimum pack thereof offered for retail sale, the maximum retail price of that formulation, with the words "Maximum Retail Price" preceding it and the words 'inclusive of all taxes' succeeding it.

Para 26 lays down that no person shall sell any formulation to any consumer at a price exceeding the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is less.

Recovery of overcharged amount under DPCO 1987 & 1995:

Under the provisions of this Order, the government shall, by notice, require the manufacturers, importers, distributors, or as the case may be, to deposit the amount accrued due to the charging of prices higher than those fixed or notified by the government under the provisions of the Drugs (Prices Control) Order, 1987, and the Drug (Prices Control) Order, 1995.

The margin of retailer & maximum retail price:

Paragraph 7 lays down that while fixing a ceiling price for scheduled formulations and retail prices of new drugs, sixteen percent of the price to the retailer as a margin to the retailer shall be allowed.

Para 8 specifies that the maximum retail price of scheduled formulations shall be fixed by the manufacturers on the basis of the ceiling price notified by the Government plus local taxes wherever applicable.

Even the loose quantities of any formulation shall not be sold at a price that is in excess of the pro-rata price of the formulation.

Click for latest notification of NPPA / DPCO

DPCO order

Drugs (Price Control) Amendment Order 2019

Drugs-Price-Control-Amendment-Order-2019

Drugs (Prices Control) Order, 2013 (DPCO)

Drugs-Price-Control-Order-2013

Drugs (Prices Control) Order, 1995 (DPCO)

Drugs-Price-Control-Order-1995

Drugs (Price Control) Order 1979 (DPCO)

Drugs-Price-Control-Order-1979

Click to read more articles on DPCO 2013

DPCO – Schedule-I

Click below link

Schedule-1 amendment S.O.-508E-dt-01-02-2021-Amendment-in-Schedule-I-of-the-DPCO-2013

Schedule-I – S.O.-701E-dt-10-03-2016-Drugs-Price-Control-Amendment-Order-2016-Regarding-Schedule-I-Drugs-and-doage-form

Price List

2022

S.O. 5939(E) dt 19-12-2022 NPPA has fixed the Ceiling price of 12 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022) based on the decision of 105th Authority meeting dated 15.12.2022

S.O.-5939E-dt-19-12-2022-NPPA-has-fixed-Ceiling-price-of-12-scheduled-formulations-under-Drugs-Prices-Control-Order-2013-NLEM-2022-based-on-the-decision-of-105th-Authority-meeting-dated-15.12.2022

S.O. 5938(E) dt 19-12-2022 NPPA has revised the Ceiling price of 107 scheduled formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022) based on the decision of 105th Authority meeting dated 15.12.2022

S.O.-5938E-dt-19-12-2022-NPPA-has-revised-Ceiling-price-of-107-scheduled-formulations-under-Drugs-Prices-Control-Order-2013-NLEM-2022-based-on-the-decision-of-105th-Authority-meeting-dated-15.12.2022

S.O. 5937(E) dt 19-12-2022 NPPA has fixed retail prices of 10 formulations under Drugs (Prices Control) Order, 2013 based on the decision of the 105th Authority meeting dated 15.12.2022

S.O.-5937E-dt-19-12-2022-NPPA-has-fixed-retail-prices-of-10-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-105th-Authority-meeting-dated-15.12.2022

S.O. 5511 (E) dt 28-11-2022 NPPA has fixed retail prices of 01 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 104th Authority meeting dated 23.11.2022

S.O.-5511-E-dt-28-11-2022-NPPA-has-fixed-retail-prices-of-01-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-104th-Authority-meeting-dated-23.11.2022

S.O. 5388(E) dt 18-11-2022 NPPA has fixed retail prices of 40 formulations under DPCO 2013 based on the decision of the 103rd Authority meeting dated 10.11.2022.

S.O.-5388E-dt-18-11-2022-NPPA-has-fixed-retail-prices-of-40-formulations-under-DPCO-2013-based-on-the-decision-of-103rd-Authority-meeting-dated-10.11.2022.

S.O. 4595(E) dt 29-09-2022 Extension Revised ceiling price of Dextrose Injection in 100ml pack having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4595E-dt-29-09-2022-Extension-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4594(E) dt 29-09-2022 Extension Revised ceiling price of Mannitol Injection 20% in 100ml pack having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4594E-dt-29-09-2022-Extension-Revised-ceiling-price-of-Mannitol-Injection-20-in-100ml-pack-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4593(E) dt 29-09-2022 Extension Revised ceiling price of Metronidazole Injection IP in 100ml pack having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4593E-dt-29-09-2022-Extension-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4592(E) dt 29-09-2022 Extension of revised ceiling price of Ringer Lactate Injection having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4592E-dt-29-09-2022-Extension-of-revised-ceiling-price-of-Ringer-Lactate-Injection-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4591(E) dt 29-09-2022 Extension of revised ceiling price of IV Fluid Injection having special features under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4591E-dt-29-09-2022-Extension-of-revised-ceiling-price-of-IV-Fluid-Injection-having-special-features-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4590(E) dt 29-09-2022 Extension of revised price of Liquid Medical Oxygen (LMO) and Oxygen Inhalation (Medicinal Gas) in cylinder under Drugs (Prices Control) Order, 2013 based on the decision of Authority meeting dated 27

S.O.-4590E-dt-29-09-2022-Extension-of-revised-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-Authority-meeting-dated-27

S.O. 4589(E) dt 29-09-2022 Extension of revised ceiling price of Heparin Injection under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022.

S.O.-4589E-dt-29-09-2022-Extension-of-revised-ceiling-price-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4588(E) dt 29-09-2022 NPPA has fixed retail prices of 40 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 102nd Authority meeting dated 27.09.2022

S.O.-4588E-dt-29-09-2022-NPPA-has-fixed-retail-prices-of-40-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-102nd-Authority-meeting-dated-27.09.2022.

S.O. 4343(E) dt 15-09-2022 Notification regarding extension of Knee implants under Drugs (Prices Control) Order, 2013.

S.O.-4343E-dt-15-09-2022-Notification-regarding-extension-of-Knee-implants-under-Drugs-Prices-Control-Order-2013.

S.O. 4342(E) dt 15-09-2022 NPPA has fixed retail prices of 1 formulation under Drugs (Prices Control) Order, 2013 (WPA) based on the decision of 101st Authority meeting dated 07.09.2022.

S.O.-4342E-dt-15-09-2022-NPPA-has-fixed-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013-WPA-based-on-the-decision-of-101st-Authority-meeting-dated-07.09.2022.

S.O. 4341(E) dt 15-09-2022 NPPA has fixed retail prices of 36 formulations under the Drugs (Prices Control) Order, 2013 based on the decision of the 101st Authority meeting dated 07.09.2022.

S.O.-4341E-dt-15-09-2022-NPPA-has-fixed-retail-prices-of-36-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-101st-Authority-meeting-dated-07.09.2022.

OM dated 25.08.2022 relating to fixation of Ceiling Price of Sodium Chloride 0.45% Injection.

OM-dated-25.08.2022-relating-to-fixation-of-Ceiling-Price-of-Sodium-Chloride-0.45-Injection.

S.O. 4002(E) dt 24-08-2022 NPPA has fixed retail prices of 45 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 100th Authority meeting dated 05.08.2022.

S.O.-4002E-dt-24-08-2022-NPPA-has-fixed-retail-prices-of-45-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-100th-Authority-meeting-dated-05.08.2022.

S.O. dt 29-07-2022 Notification regarding extension of capping of trade margin of 5 Medical Devices

S.O.-dt-29-07-2022-Notification-regarding-extension-of-capping-of-trade-margin-of-5-Medical-Devices

S.O. 2983(E) dt 30-06-2022 Notification regarding extension of price regulation on Oxygen Concentrator

S.O.-2983E-dt-30-06-2022-Notification-regarding-extension-of-price-regulation-on-Oxygen-Concentrator

S.O. 2982(E) dt 30-06-2022 Notification regarding extension of price regulation on LMO and Oxygen Inhalation

S.O.-2982E-dt-30-06-2022-Notification-regarding-extension-of-price-regulation-on-LMO-and-Oxygen-Inhalation

S.O. 2981(E) dt 30-06-2022 NPPA has fixed the retail prices of 84 new drugs based on the decision taken in 99th Authority meeting dated 28.06.2022

S.O.-2981E-dt-30-06-2022-NPPA-has-fixed-the-retail-prices-of-84-new-drugs-based-on-the-decision-taken-in-99th-Authority-meeting-dated-28.06.2022

S.O. 2465(E) dt 30-05-2022 Notification regarding extension of TMR notification on Oxygen Concentrators

S.O.-2465E-dt-30-05-2022-Notification-regarding-extension-of-TMR-notification-on-Oxygen-Concentrators

S.O. 2166 (E) DT 09-05-2022 NPPA has revised retail price of 1 formulation under Drugs (Prices Control) Order, 2013 based on review order.

S.O.-2166-E-DT-09-05-2022-NPPA-has-revised-retail-price-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-review-order.

S.O. 2165(E) Dt 09-05-2022 NPPA has fixed retail prices of 18 formulations under Drugs (Prices Control) Order, 2013 the price of which were applied earlier in the 96th Authority meeting dated 24.03.2022.

S.O.-2165E-Dt-09-05-2022-NPPA-has-fixed-retail-prices-of-18-formulations-under-Drugs-Prices-Control-Order-2013-the-price-of-which-were-applied-earlier-in-the-96th-Authority-meeting-dated-24.03.2022.

S.O. 2164(E) Dt 09-04-2022 NPPA has fixed retail prices of 66 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 97th Authority meeting dated 06.05.2022.

S.O.-2164E-Dt-09-04-2022-NPPA-has-fixed-retail-prices-of-66-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-97th-Authority-meeting-dated-06.05.2022.

S.O. 1833(E) dt 18-04-2022 NPPA has fixed retail prices of 15 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022

S.O.-1833E-dt-18-04-2022-NPPA-has-fixed-retail-prices-of-15-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022

S.O. 1782(E) dt 12-04-2022 NPPA has fixed retail prices of 23 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 96th Authority meeting dated 24.03.2022

S.O.-1782E-dt-12-04-2022-NPPA-has-fixed-retail-prices-of-23-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-96th-Authority-meeting-dated-24.03.2022

S.O. 1508(E) dt 30-03-2022 NPPA has fixed ceiling prices of Liquid Medical Oxygen, Medical Inhalation under Drugs (Prices Control) Order, 2013

S.O.-1508E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Liquid-Medical-Oxygen-Medical-Inhalation-under-Drugs-Prices-Control-Order-2013

S.O. 1507(E) dt 30-03-2022 NPPA has fixed ceiling prices of Heparin Injection under Drugs (Prices Control) Order, 2013

S.O.-1507E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013

S.O. 1506(E) dt 30-03-2022 NPPA has fixed ceiling prices of Dextrose under Drugs (Prices Control) Order, 2013

S.O.-1506E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Dextrose-under-Drugs-Prices-Control-Order-2013

S.O. 1505(E) dt 30-03-2022 NPPA has fixed ceiling prices of Mannitol under Drugs (Prices Control) Order, 2013

S.O.-1505E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Mannitol-under-Drugs-Prices-Control-Order-2013

S.O. 1504(E) dt 30-03-2022 NPPA has fixed ceiling prices of Metronidazole under Drugs (Prices Control) Order, 2013

S.O.-1504E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-Metronidazole-under-Drugs-Prices-Control-Order-2013

Click to read more on NLEM

S.O. 1503(E) dt 30-03-2022 NPPA has fixed ceiling prices of 9 formulations under Drugs (Prices Control) Order, 2013

S.O.-1503E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-9-formulations-under-Drugs-Prices-Control-Order-2013

S.O. 1502(E) dt 30-03-2022 NPPA has fixed ceiling prices of 2 Coronary stents under Drugs (Prices Control) Order, 2013

S.O.-1502E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-2-Coronary-stents-under-Drugs-Prices-Control-Order-2013

S.O. 1501(E) dt 30-03-2022 NPPA has fixed ceiling prices of 4 formulations under Drugs (Prices Control) Order, 2013

S.O.-1501E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-4-formulations-under-Drugs-Prices-Control-Order-2013

S.O. 1500(E) dt 30-03-2022 NPPA has fixed ceiling prices of 8 formulations under Drugs (Prices Control) Order, 2013

S.O.-1500E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-8-formulations-under-Drugs-Prices-Control-Order-2013

S.O. 1499(E) dt 30-03-2022 NPPA has fixed ceiling prices of 872 formulations under Drugs (Prices Control) Order, 2013

S.O.-1499E-dt-30-03-2022-NPPA-has-fixed-ceiling-prices-of-872-formulations-under-Drugs-Prices-Control-Order-2013

OM. dt 25-03-2022 Movement in Wholesale Price Index (WPI) for the preceding calendar year 2021

OM.-dt-25-03-2022-Movement-in-Wholesale-Price-Index-WPI-for-the-preceding-calendar-year-2021

S.O. 796(E) dt 18-02-2022 NPPA has fixed ceiling prices of 19 formulations under Drugs (Prices Control) Order, 2013

S.O.
https://thehealthmaster.com/drugs/national-pharmaceutical-pricing-authority-nppa/

Zydus Lifesciences Ltd. announced that it has received final approval from the US Food and Drug Administration (USFDA) to market its generic version of Triazolam tablets, which are used to treat insomnia in the short term.

The approval granted by the USFDA is to market Triazolam tablets of strengths 0.125 mg and 0.25 mg, the company said in a regulatory filing.

The medicine is used on a short-term basis to treat insomnia—difficulty falling asleep or staying asleep.

Click for ore articles on USFDA

It works by slowing activity in the brain to allow sleep.

It will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, the company said.

Triazolam tablets had annual sales of USD 11.7 million in the US, the company said, citing IQVIA MAT September 2022 data.

Other drugs approval by USFDA

USFDA approves this monoclonal antibody to treat multiple sclerosis

USFDA gives final approval to this breast cancer injection

USFDA gives approval for Fulvestrant injection

USFDA gives approval for this Genetic Disorder drug

USFDA gives approval for Lymphoma Therapy

USFDA gives approval for Pregabalin capsules

Antibiotics need to be developed urgently for newborns: Experts

Pharma companies told to ensure drug stocks

Drug recall: 4 lots of Quinapril Tablets recalled due to this reason

USFDA approves this monoclonal antibody to treat multiple sclerosis

IPC launches 10 new impurities standards

CDSCO and States starts joint inspections of Drug Manufacturing Units

DCGI calls for registering (MDTLs) Medical Devices Testing Laboratories

Confession in criminal proceedings: Ground for conviction ?

Registration for sale of Medical Devices: Procedure and conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/31/usfda-gives-final-approval-for-this-insomnia-drug/

There is an urgent need to develop antibiotics for newborn babies, a population that is particularly vulnerable to antibiotic resistance, according to leading global public health experts, including those from India.

Recent estimates show about 2.3 million newborns die of severe bacterial infections each year, while an increasing number become resistant to currently-used antibiotics, the experts said in a report published in the December 2022 Bulletin of the World Health Organization (WHO).

Click for more articles on Antibiotics and its resistance

Over the last decade, AMR has worsened to the point where 50 to 70 percent of common pathogens show a high degree of resistance to available first- and second-line antibiotics, they said.

The paper is co-authored by international experts in the field of anti-microbial resistance (AMR), including those from the Global Antibiotic Research and Development Partnership (GARDP) and the All India Institute of Medical Sciences (AIIMS).

Click for more articles on WHO

The authors noted that despite substantial progress in medical research and a steep decline in the number of children under the age of five who die of preventable diseases, many problems related to child health remain to be tackled.

Severe bacterial infections are one of them.

“There is an urgent need to identify high-priority antibiotics to understand which ones work best and safely in children, and then make them available where they are needed,” said Mike Sharland from St George’s, University of London (SGUL), and member, AMR Programme, Penta – Child Health Research.

Click for more articles on Bacterial Infections

“By achieving global consensus, we can streamline the process of antibiotic development, allow for faster access to antibiotics, and reduce the burden of AMR on the vulnerable neonatal population,” added Manica Balasegaram, Executive Director, GARDP.

The report also highlights how collaborative antibiotic development and access network specifically targetting newborns could also prove valuable compared to single independent studies.

A successful example, the authors noted, has been the collaboration between GARDP, Penta – Child Health Research, SGUL, and other partners on a recent global observational study of 3,200 babies with neo-natal sepsis across 19 hospitals in 11 countries.

They are also partnering on an upcoming clinical trial, which will start in South Africa within the next few months before being expanded to other countries.

Despite a rising number of new-born deaths caused by AMR, very few effective antibiotics have been adequately studied to treat serious bacterial infections such as neo-natal sepsis, the authors said.

As many as 40 antibiotics have been approved for use in adults since 2000, but only four have included dosing information for newborns in their labels, they said.

According to the report, ethical concerns, logistical issues, and regulatory requirements have made it difficult to conduct clinical research in newborns.

According to the report, there is a long delay in completing paediatric regulatory studies, and they are also not globally harmonized to demonstrate clinical utility in newborns.

Pharma companies told to ensure drug stocks

Drug recall: 4 lots of Quinapril Tablets recalled due to this reason

USFDA approves this monoclonal antibody to treat multiple sclerosis

CDSCO orders audits of Pharma Manufacturers & Importers for Pharmacovigilance system

IPC launches 10 new impurities standards

CDSCO and States starts joint inspections of Drug Manufacturing Units

DCGI calls for registering (MDTLs) Medical Devices Testing Laboratories

Confession in criminal proceedings: Ground for conviction ?

Registration for sale of Medical Devices: Procedure and conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/31/antibiotics-need-to-be-developed-urgently-for-newborns-experts/

NEW DELHI: Union health minister Mansukh Mandaviya asked pharma companies to ensure adequate stocks and availability of all drugs, including those for COVID management, in the supply chain up to the retail level amid a rise in COVID-19 cases in some countries.

He reviewed the status, adequacy of Covid-19 management drugs and production capacities with representatives of pharma companies through a virtual conference so that India is equipped to effectively handle any situation, officials said.

According to a statement issued by the health ministry, the minister was briefed regarding the evolving global scenario in the meeting.

Click for more articles on Pharma Companies

Mandaviya appreciated the pharma companies for their invaluable contribution during the pandemic in the country, the statement said.

"India's pharmaceutical industry is robust, resilient, and responsive." "It is due to their strength that we could not only meet our low demand during the pandemic, but also be in a position to supply medicines to 150 countries," he said.

This was achieved without any fall in quality or hike in the price of the medicines, the health minister said.

The pharma companies were asked to keep a close watch on the global supply chain scenario, the health ministry statement said.

They were also asked to closely monitor production and availability of APIs as well as formulations of essential medicines for Covid management, it added.

Drug recall: 4 lots of Quinapril Tablets recalled due to this reason

USFDA approves this monoclonal antibody to treat multiple sclerosis

CDSCO orders audits of Pharma Manufacturers & Importers for Pharmacovigilance system

IPC launches 10 new impurities standards

NPPA releases draft calculation sheet for ceiling price revision of 35 formulations

CDSCO and States starts joint inspections of Drug Manufacturing Units

DCGI calls for registering (MDTLs) Medical Devices Testing Laboratories

Confession in criminal proceedings: Ground for conviction ?

Registration for sale of Medical Devices: Procedure and conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/30/pharma-companies-told-to-ensure-drug-stocks/

How to get Hospital registered as RMIRMI – Recognised Medical Institute

If a hospital or institute uses the following essential narcotic drugs, registration is required under the Narcotic Drugs and Psychotropic Substances (Third Amendment) Rules, 2015, which has come into force vide Gazette Notification GSR 359(E) dated 5th May 2015.

Notified Essential Narcotic Drugs (END)

● Morphine● Codeine● Methadone● Hydrocodone● Oxycodone● Fentanyl

Also read: Telemedicine facility in hospitals

The hospital or institute is required to get itself registered as a recognized medical institute by the State Drugs Controller of the state.

Abbreviations:

NDPS: Narcotic Drugs and Psychotropic SubstancesRMI: Recognized Medical InstituteDMP: Designated Medical PractitionerRMP: Regd. Medical PractitionerEND: Essential Narcotics DrugsSDC: State Drugs ControllerASDC: Asstt. State Drugs ControllerSDCO: Senior Drugs Control Officer DCO: Drugs Control Officer

How to obtain registration of RMI

The list of documents required for obtaining registration as a recognized medical institute is provided below.

Procedure for how to get Hospital registered as RMI

The hospital or institute shall submit the original application for registration or renewal of the Certificate of Recognition as RMI in Form 3F, duly filled out and with the requisite documents, to the State Drug Controller of the state.

Copy of the same shall be forwarded to the concerned Asstt. State Drugs Controller / Senior Drugs Control Officer / Drugs Control Officer (as the case may be) of the area.

Also read: Haryana: Hospitals get quality certificate

Documents required for registration of Hospital as RMI

The application shall be accompanied by:

- Covering letter addressed to the SDC signed by the Medical Officer in charge of the Hospital / Institute.

- Application for issue / renewal of Certificate of Recognition as RMI in Form 3F.

- Estimate of annual requirement of Essential Narcotic Drugs (END) in Form 3J.

- Constitution of Hospital / Institute.

- ROC certificate of Hospital / Institute.

- List of Directors / Partners with address

- Affidavits of Directors / Partners / Proprietor

- MoA of Hospital / Institute

- DIR-12 of all directors

- Partnership deed

- BOD Resolution

- Authorization letter for In-Charge

- Affidavit of In-Charge

- Authorization letter for Designated Medical Practitioner (DMP)

- Affidavit of DMP

- List of Regd. Medical Practitioners (RMP) with Qlf., Regn. No. Mobile No etc.

- Self attested copies of Registration and Qualification Certificates of the in-charge / DMP / RMPs of RMI (in case of Fresh RMI application / change in Medical Officer).

- Copy of the certificate of training in pain relief and palliative care training as notified in NDPS Rules (in case of Fresh RMI application / change in DMP).

- Storage of END ( Cupboard with double lock system)

- Blue print map of the premises.

- Ownership / rent / lease deed

- Electricity bill of Hospital / Institute

- Pan card of the Hospital / Institute

- Fire safety certificate

- Genset

- Other medical certificate ( PNDT, MTP etc)

- Annual return of procurement / disbursement of END in Form 3-I (in case of Renewal of RMI).

- Original of RMI certificate in Form 3G (in case of renewal of RMI).

- Details of suppliers from whom the END are procured.

Submit your application to the State Drugs Controller/Licensing Authority in your area after completing all the required documents.

Note: Requirements of some of the documents and procedure for submission of application may vary from State to State

Also read: Incentives to private hospitals to boost World’s biggest health insurance program

Checklist for RMI

Download the checklist in a pdf file for obtaining registration as Recognized Medical Institute. Click below link

NDPS-RMI-Checklist

Forms

Download the
below pdf files for various Forms which are required after obtaining
registration as Recognized Medical Institute.

Form-3F

Form-3J

Submit your application to the State Drugs Controller/Licensing Authority of your area after completing all the required documents.

Specimen Affidavits for RMI

Download the below pdf files for specimen affidavits which are required after obtaining registration as Recognized Medical Institute.

Affidavits-for-RMI

Note: Requirements of some of the documents and procedures for submission of application may vary from State to State

Conditions for RMI:

- Certificate of Recognition (RMI) shall be valid up to 3 years.

- Application for the renewal of RMI shall be made to the SDC at least 60 days before the expiry.

- Every RMI shall be liable to periodic inspections by the ASDC / SDCO / DCO authorized by the SDC.

- In the event of change in constitution of RMI, the current Recognition shall shall be deemed to be valid for a maximum period of 90 days of such change.

- Change in DMP of the RMI shall be intimated to the SDC within 7 days.

- Change in name of the RMI shall be intimated to the SDC immediately.

- Copy of every consignment note of END in Form 3C dully filled and signed by both the consigner and consignee, shall be forwarded to the SDC. Original of the same shall be retained by the RMIs for a period of 2 years from the date of transaction and such records shall be produced before the officer on demand during inspection.

- Every RMI shall also maintain a separate record as per Form 3E for each patient and such records shall be retained for period of 2 years from the date of last entry. This record shall be produced before the officer on demand during inspection.

- Every RMI shall maintain daily accounts of all receipts and dispensed quantities for each END as per Form 3H, which shall be retained for a period of 2 years from the date of last entry. This record shall be produced before the officer on demand during inspection.

- Every RMI shall submit an estimate of its annual requirement of END in Form 3-J by 30th November of the proceeding calendar year to the SDC.

- If the disbursement of the END exceeds the estimate of annual requirement in Form 3J, a revised estimate shall be submitted in Form 3J in due course.

- Details of suppliers of END other than regular suppliers shall be intimated in due course.

- RMIs shall file annual return of procurement / disbursement of essential narcotic drugs for a calendar year on or before 31st of March of the subsequent year in Form 3 I to the SDC.

- The Medical Officer in charge of the RMI shall record a brief justification were the annual disbursement is more than 10% of the estimate or revised estimate along with Form 3 I.

- RMI may surrender its recognition by giving not less than 30 days notice in writing to the SDC.

Forms for regular reporting

List of Forms for for regular reporting to the authorities are provided below. Download the pdf file and prepare the reports accordingly.

Form-3E

Form-3H

Form-3-I

For notifications of RMI, click below link:

Notifications – RMI

Disposal of Essential Narcotic drugs

By a registered RMI (Hospital)

Rule 52S: Disposal of drugs on surrender of recognition:

On surrender of the recognition, the essential narcotic drugs as may be in the possession of the RMI shall be disposed of in such manner, including transfer to another RMI, as may be specified by the Controller of Drugs

By a manufacturer

Rule 45A: Destruction of drugs:

(1) A licensee seeking to destroy the drug shall apply to the Narcotic Commissioner in such form and manner as may be specified by the Narcotic Commissioner

(2) The Narcotic Commissioner shall, within a period of thirty days from the date of receipt of an application under sub-rule (1), appoint a committee comprising of a Gazetted Officer in the office of the Narcotic Commissioner, or Narcotic Control Bureau constituted vide notification number S.O. 96(E) dated 17-03-1986, the Superintendent of Central Excise of the concerned range, and an authorized representative of the applicant for supervising the destruction of the drug and such destruction shall be carried out within a period of thirty days from the appointment of the committee.

(3) The destruction of the drug shall be carried out in accordance with the provision of the relevant laws for the time being in force.

By an Authorized person or registered medical practitioner

Rule 52M: Disposal of stocks of essential narcotic drugs on expiry, surrender, cancellation of authorization:

(1) On the expiry, cancellation, or surrender of an authorized person's authorization, any stock of essential narcotic drugs in his possession shall be disposed of in the manner specified by the Controller of Drugs.

(2) The expired stock of essential narcotic drugs as may be in the possession of an authorized person or a registered practitioner shall be destroyed in such manner as may be specified by the Controller of Drugs.

Click below link to download the notification

Narcotic Drugs & Psychotropic Substance (Third Amendment) Rules, 2015 which has come into force vide Gazette notification GSR 359(E) dated 5th May 2015

GSR-359-E-Dt.-05-05-15-Recognised-Medical-Institute

To download the checklist, forms and notification in pdf file. Click here

Compiled by:Rakesh Dahiya, SDCO cum Licensing Authority, FDA Haryana

Click here to read other articles of this Author
https://thehealthmaster.com/2019/12/23/how-to-get-hospital-registered-as-rmi/

Kidney disease is a major health care burden in both the developing and developed worlds, with a global prevalence of approximately 850 million people worldwide.

The global burden of Chronic Kidney Disease (CKD) is increasing and is projected to become the fifth most common cause of deaths globally by 2040.

The costs of dialysis and transplantation consume 2-3 per cent of the annual healthcare budget in high-income countries, and is spent on less than 0.03 per cent of the total population of these countries. 

In low-income and middle-income countries, most people with kidney failure have insufficient access to dialysis and kidney transplantation.

Disease like Diabetes, Obesity and Hypertension are on the rise and in many centres, more so in the developing world, are not adequately treated and monitored, leading to a rise in the incidence and also in the acceleration of kidney disease in select populations.

The use of native and alternate forms of medicines to treat non-kidney ailments and the use of painkillers and kidney-toxic antibiotics often results in kidney disease, which adds tremendously to the global burden.

Also read | Do not share your prescription medicine!

Tertiary prevention translates to management of mortality and morbidity by treating advanced disease like early and timely institution of renal replacement therapies in the form of dialysis and kidney transplant respectively.

Primary prevention of kidney disease requires modification of risk factors, including diabetes mellitus and hypertension, unhealthy diets, structural abnormalities of the kidney and urinary tracts, or nephrotoxicity levels.

For more ARTICLES on health and fitness, click here

Preventative primary interventions include promoting healthy lifestyles, including physical activity and healthy diets; screening for patients at higher CKD risk with the aid of urine and blood tests; and keeping screening data in a CKD registry.

In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimisation and glycemic control, is the main goal of education and clinical interventions which can be achieved by low salt, protein, as well as plant- and pharmacotherapy.

In patients with advanced CKD, management of co-morbidities, such as uremia and cardiovascular disease, is of high priority.

By Dr Partha Pradeep Shetty The author is consultant - nephrologist transplant physician, Vikram Hospital
https://thehealthmaster.com/2021/01/19/how-to-keep-your-kidneys-health-in-check/